Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden
Mingrui Zhu(Harold C. Simmons Comprehensive Cancer Center), Esra A. Akbay(Southwestern Medical Center)
Cited by 52
Related Papers
Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity
|Journal for ImmunoTherapy of Cancer|2019|152
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice
|Genes & Development|2014|86
Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2
|RePEc: Research Papers in Economics|2020|11